DMYD BTU B Stock Overview
Develops precision medicine therapies for the treatment of autoimmune diabetes.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Diamyd Medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr13.00 |
| 52 Week High | kr15.75 |
| 52 Week Low | kr9.82 |
| Beta | 2.07 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 17.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| DMYD BTU B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -5.1% | -0.3% | 0.6% |
| 1Y | n/a | 2.9% | 16.0% |
Return vs Industry: Insufficient data to determine how DMYD BTU B performed against the Swedish Biotechs industry.
Return vs Market: Insufficient data to determine how DMYD BTU B performed against the Swedish Market.
Price Volatility
| DMYD BTU B volatility | |
|---|---|
| DMYD BTU B Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 13.2% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: DMYD BTU B has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DMYD BTU B's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 26 | Ulf Hannelius | www.diamyd.com |
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes.
Diamyd Medical AB (publ) Fundamentals Summary
| DMYD BTU B fundamental statistics | |
|---|---|
| Market cap | kr1.08b |
| Earnings (TTM) | -kr120.18m |
| Revenue (TTM) | kr282.00k |
3,843x
P/S Ratio-9.0x
P/E RatioIs DMYD BTU B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMYD BTU B income statement (TTM) | |
|---|---|
| Revenue | kr282.00k |
| Cost of Revenue | kr3.76m |
| Gross Profit | -kr3.48m |
| Other Expenses | kr116.70m |
| Earnings | -kr120.18m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
Jun 26, 2024
| Earnings per share (EPS) | -1.17 |
| Gross Margin | -1,234.75% |
| Net Profit Margin | -42,617.73% |
| Debt/Equity Ratio | 0% |
How did DMYD BTU B perform over the long term?
See historical performance and comparison